Correlation of O⁶-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity

This publication has 67 references indexed in Scilit:

• Validation of Real-Time Methylation-Specific PCR to Determine O6-Methylguanine-DNA Methyltransferase Gene Promoter Methylation in Glioma
  The Journal of Molecular Diagnostics, 2008
• A Multicenter Cohort Study of Dose-Dense Temozolomide (21 of 28 Days) for the Treatment of Recurrent Anaplastic Astrocytoma or Oligoastrocytoma
  Cancer Investigation, 2008
• Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide Treatment
  Clinical Cancer Research, 2007
• Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)
  British Journal of Cancer, 2006
• Differential Requirement for DNA Methyltransferase 1 in Maintaining Human Cancer Cell Gene Promoter Hypermethylation
  Cancer Research, 2006
• How Lymphotoxic Is Dose-Intensified Temozolomide? The Glioblastoma Experience
  Journal of Clinical Oncology, 2005
• Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
  New England Journal of Medicine, 2005
• Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules
  British Journal of Cancer, 2003
• A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
  British Journal of Cancer, 2000
• Transfection and expression of human O⁶-methylguanine-DNA methyltransferase (MGMT) cDNA in Chinese hamster cells: the role of MGMT in protection against the genotoxic effects of alkylating agents
  Carcinogenesis: Integrative Cancer Research, 1991